McKesson Corporation (MCK)

Revenue

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
North American Pharmaceutical Revenue	336.65B	304.51B
North American Pharmaceutical Revenue Growth	10.56%	16.50%
Oncology & Multispecialty Revenue	48.42B	36.86B
Oncology & Multispecialty Revenue Growth	31.36%	20.90%
Prescription Technology Solutions Revenue	5.81B	5.22B
Prescription Technology Solutions Revenue Growth	11.29%	9.37%
Medical Surgical Solutions Revenue	11.51B	11.38B
Medical Surgical Solutions Revenue Growth	1.12%	0.63%
Other Segment Revenue	1.04B	1.09B
Other Segment Revenue Growth	-3.96%	7.00%
Revenue (Total)	403.43B	359.05B
Revenue (Total) Growth	12.36%	16.22%

EBIT

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
North American Pharmaceutical Operating Profit	3.66B	2.95B
North American Pharmaceutical Operating Profit Growth	24.21%	25.96%
Oncology & Multispecialty Operating Profit	1.15B	767.00M
Oncology & Multispecialty Operating Profit Growth	49.80%	8.49%
Prescription Technology Solutions Operating Profit	1.04B	875.00M
Prescription Technology Solutions Operating Profit Growth	19.31%	4.79%
Medical Surgical Solutions Operating Profit	938.00M	779.00M
Medical Surgical Solutions Operating Profit Growth	20.41%	-18.43%
Other Segment Operating Profit	590.00M	54.00M
Other Segment Operating Profit Growth	992.59%	-5.26%
Operating Income (Other)	-1.17B	-998.00M
Operating Income (Total)	6.21B	4.42B
Operating Income (Total) Growth	40.48%	13.12%

Capital Expenditures

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
US Pharmaceutical Capital Expenditures	241.00M
US Pharmaceutical Capital Expenditures Growth	24.87%
Prescription Technology Solutions Capital Expenditures	11.00M
Prescription Technology Solutions Capital Expenditures Growth	-64.52%
Medical Surgical Solutions Capital Expenditures	163.00M
Medical Surgical Solutions Capital Expenditures Growth	2.52%
International Capital Expenditures	107.00M
International Capital Expenditures Growth	42.67%

Data Source: Fiscal.ai Last updated: May 7, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 19, 2026

Data Sources Report a data error